louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04624165: Patient Perspective of Telemedicine in Gynecology Oncology
Official title: Patient Perspective of Telemedicine in Gynecology Oncology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Oncology
Keywords: Telemedicine
Lead sponsor: TriHealth Inc.
Sponsor class: OTHER
First posted: 2020-11-10
Enrollment: 116
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: o Eligible patients would be at least 18 years of age, and currently being treated by one of the providers within the gynecologic oncology group.

Brief summary: Research question: do patients in a gynecologic oncology practice value the use of telemedicine as an adjunct to in-person visits and in what circumstances might patients not find these visits to be sufficient?

Detailed description: In the United States, 14.8 million women live greater than 50 miles away from the closest gynecology oncologist underscoring the need for increased implementation of telemedicine. In consideration of the COVID-19 outbreak, recommendations were made to organize goals of therapy by prioritizing curative intent and utilizing telemedicine to manage current therapies. Research regarding telemedicine, its benefits, and patient perspectives in other specialties has been reported, however there appears to be a dearth of information in the field of gynecologic oncology. Our study aims to seek patients' perspective of telemedicine and whether implementation for extended office visits, teleconsultations and more are feasible and valuable to them.

Eligibility criteria: o Eligible patients would be at least 18 years of age, and currently being treated by one of the providers within the gynecologic oncology group.

Primary outcomes:
measure: Patient's perspective on telemedicine on a Likert Scale
timeFrame: Through survey completion, an average of 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: TriHealth - Good Samaritan and Bethesda North Hospitals
state: Ohio
Study officials:
affiliation: TriHealth Inc.
name: Robert Neff, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04846465: Femoral Neck-shaft Angle in Sohag Population
Official title: Femoral Neck-shaft Angle in Sohag Population: Variation Relating to Age and Sex.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hip Abnormalities
Femur; Angulation
Urinary Stone
Lower Limb Arterial Embolus
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-04-15
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants who underwent computed tomography (CT) of the femur and acetabulum in departments of Radiology in Sohag University Hospital

Brief summary: The femur or thigh bone is the strongest and longest bone of the body and about 45 cm long in an average man that means approximately one fourth of the height of individual. It has upper end, lower end and a cylindrical shaft. Upper end consists of head, neck. The neck is about 5 cm long, connects the head to the shaft and is directed upward, medially and slightly forward and making an angle about 125 with shaft but the angle is wider in children. The neck-shaft angle (NSA ) is defined as the angle formed by the neck axis and long axis of the shaft of femur.The knowledge of the neck shaft angle is valuable in the diagnosis and treatment of fracture of upper end of femur.

The aim of the study is :

1. to evaluate the normal values of femoral neck-shaft angle
2. to detect factors that may affect this angle as age, and sex, in Egyptian adults from Sohag.


Eligibility criteria: Inclusion Criteria:

* Adults, eligible and adequate imaging data for measurement, and absence of fracture, arthritis, tumor, deformity, or surgery on the proximal part of the femur or any disorder that may affect measurements of femoral neck-shaft angle

Exclusion Criteria:

* Adults with incomplete imaging data; and fracture, arthritis, tumor, deformity, or surgery on the proximal part of the femur

Primary outcomes:
measure: To measure femoral neck-shaft angle ( NSA) .
timeFrame: 16 weeks following the startpoint of the study
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
References:
Clinical trial NCT00187265: Trip HF Study: Triple Resynchronization in Paced Heeart Failure Patients
Official title: Triple Resynchronization in Paced Heart Failure Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Ventricular Dyssynchrony
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2005-09-16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the feasibility of permanent biventricular pacing using three ventricular leads, and its efficacy in terms of inter and intra-ventricular resynchronization, in patients with congestive heart failure and a non-functional atrium (chronic AF).


Eligibility criteria: Inclusion Criteria:

• NYHA class III-IV congestive heart failure, in spite of optimal medical treatment for their congestive heart failure for 1 month.

The medical treatment must include a 40 mg/day minimum dose of furosemide (or equivalent);

* Permanent atrial fibrillation (AF);
* Left ventricular ejection fraction (LVEF) ≤ 35%;
* Indication for a pacemaker implantation for a permanent and symptomatic bradycardia, or already implanted pacemaker under the condition that leads positioning corresponds to the criteria described in the protocol;
* Aortic pre-ejection delay at least equal to 140 ms.

Exclusion Criteria:

* Indication for a cardiac defibrillator;
* Having presented a myocardial infarct within the previous 3 months;
* Having undergone cardiac surgery or coronary revascularization procedure within the previous 3 months, or being scheduled for such procedures;
* Presenting chronic pulmonary insufficiency;
* Patients whose congestive heart failure requires the use of an intravenous inotropic support;
* Presenting a dysthyreosis;
* Having a life expectancy of less than one year, for other reasons than the congestive heart failure;
* Unable to be followed-up in the scope of the study for geographical reasons;
* Having refused to give their consent;
* Minors (age \< 18 years) and pregnant women.

Primary outcomes:
measure: Z-ratio
Secondary outcomes:
Other outcomes:
Locations:
city: Rennes
country: France
facility: Department of Cardiology - CHU Pontchaillou
Study officials:
affiliation: CHU Pontchaillou Rennes France
name: Jean-Claude Daubert
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00005265: Natural History of Coronary Heart Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Diseases
Coronary Disease
Myocardial Infarction
Heart Diseases
Death, Sudden, Cardiac
Heart Failure, Congestive
Heart Failure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Sponsor class: NIH
First posted: 2000-05-26
Sex: MALE
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: To examine the natural history of mortality due to coronary heart disease in post-myocardial infarction patients from the Beta-Blocker Heart Attack Trial (BHAT) and the Aspirin Myocardial Infarction Study (AMIS).

Detailed description: BACKGROUND:

In January 1990, the National Heart, Lung, and Blood Institute issued a Program Announcement establishing a Small Grants Program to provide limited support to extend analyses of research data generated by clinical trials, population research, and demonstration and education studies. This study used data collected in two completed clinical trials, the BHAT and AMIS.

DESIGN NARRATIVE:

Study endpoints included all-cause mortality, cause-specific mortality such as sudden death, recurrent and non-fatal myocardial infarction, and incident congestive heart failure. Univariate and multivariate analyses of baseline data variables from BHAT were conducted to determine which were predictive of study endpoints. Baseline variables included sociodemograhic characteristics, medical history, medication use, physical examination finds, and electrocardiographic characteristics. Baseline characteristics found to be predictive of study endpoints in the BHAT placebo group were examined in the AMIS placebo group. Long- and short-term prognoses for patients suffering a transmural myocardial infarction were compared for those suffering a subendocardial infarction.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Eligibility criteria: No eligibility criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02592265: Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden
Official title: Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden and Social Participation.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Physical Disability
Economic Burden
Social Interaction
Capability
Quality of Life
Lead sponsor: Lille Catholic University
Sponsor class: OTHER
Collaborators: name: Université de Lille
name: Région Nord-Pas de Calais, France
name: La Ligue Française Contre la Sclérose en Plaques
name: Novartis
First posted: 2015-10-30
Enrollment: 233
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: At least 230 patients in secondary and tertiary centers (8) affiliated to the regional supportive care network (GSEP) in north of France.

Brief summary: The objective of this study is to measure economic burden of Multiple Sclerosis (MS) from a new point of view that includes consequences of disability on Quality Of Life (QOL), social participation and capabilities of patients and caregivers. To the investigators' knowledge, there is currently no data including intangible costs related to caregivers and calculating the overall economic cost of Multiple Sclerosis, particularly, in France.

Detailed description: The goal of this study is to evaluate prospectively the economic burden of Multiple Sclerosis (MS) in France by calculating direct costs (medical and non-medical) and indirect costs and by estimating consequences of MS on utility (QALY) of patients and caregivers in a societal perspective.

Eligibility criteria: Inclusion Criteria:

* Participant aged 18 or more
* Confirmed MS diagnosis (McDonald 2005)
* Defined type of MS according classification of Lublin and Reingold

Exclusion Criteria:

* Subject living in an institution
* Severe cognitive dysfunction preventing to answer questionnaire
* Subject already included in other clinical study (phase 1 to 3)

Primary outcomes:
measure: Annual average total health care cost of the Multiple Sclerosis by patient
timeFrame: 1 year
Secondary outcomes:
measure: Score of social participation
timeFrame: 1 year
measure: Validity of life quality measurement EQ-5D
timeFrame: 1 year
measure: Utilities measured by the Short Form-6D (SF-6D)
timeFrame: 1 year
measure: QALY
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Groupement des Hôpitaux de l'Institut Catholique de Lille
name: Arnaud KWIATKOWSKI
role: PRINCIPAL_INVESTIGATOR
affiliation: Groupement des Hôpitaux de l'Institut Catholique de LilleGroupement des Hôpitaux de l'Institut Catholique de Lille
name: Amélie LANSIAUX
role: STUDY_DIRECTOR
References:
Clinical trial NCT02865265: Pecs II Block and PaB Could be an Alternative in Breast Surgery
Official title: Association Between Ultrasound-guided Pecs II Block and Parasternal Block May Represent a Valid Alternative for the Management of Acute and Postoperative Pain Syndrome in Breast Cancer Surgery: a Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Lead sponsor: San Salvatore Hospital of L'Aquila
Sponsor class: OTHER
First posted: 2016-08-12
Enrollment: 180
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients scheduled for quadrantectomy with or without axillary dissection.

Brief summary: The association between ultrasound-guided Pecs II block and parasternal block can represent a valid alternative in the management of acute and postoperative pain syndrome after quadrantectomy with or without axillary dissection.

Detailed description: The combination of Pecs II block and PaB provides good management of postoperative pain and can be considered a viable alternative to common anesthetic procedures performed for breast cancer surgery.

Eligibility criteria: Inclusion Criteria:

* 18-75 years of age;
* American Society of Anesthesiologists (ASA) physical status I-III,
* patients scheduled for quadrantectomy with or without axillary dissection

Exclusion Criteria:

* pregnancy;
* body mass index (BMI) \>35;
* allergy to local anesthetics;
* skeletal or muscle abnormalities of the chest wall;
* presence of primary or secondary neurological diseases;
* presence of psychiatric diseases;
* history of chronic pain or neuropathic disorders;
* history of drug abuse;
* state of sepsis;
* infection
* tumors of the skin on the chest;
* primary;
* secondary coagulopathies

Primary outcomes:
measure: Pain
timeFrame: Pain was recorded at 24 months after surgery
Secondary outcomes:
measure: Neuropathic postoperative disturbances
timeFrame: Neuropathic postoperative disturbances were recorded at 24 months after surgery
measure: Patient satisfaction
timeFrame: Patient satisfaction was evaluated at 1 day after surgery
measure: Woud healing
timeFrame: Wound healing was assessed at 24 months after surgery
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00153465: University of Oklahoma Parenting Program Attrition
Official title: University of Oklahoma Health Sciences Center Parenting Program Attrition and Compliance Efficacy Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Child Abuse
Keywords: Parent training
Child maltreatment
Motivation
Program attrition
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
First posted: 2005-09-12
Enrollment: 450
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The study will examine the extent to which a group motivational intervention (ME) impacts retention, treatment compliance, and long-term outcomes in families with a history of, or high risk for, child maltreatment.

Detailed description: The field of child abuse prevention faces not only the challenge of developing and disseminating effective treatments, but the problem of high attrition rates and treatment noncompliance. This study will compare the effects of a motivational intervention with a "services as usual" orientation group on program retention, treatment compliance, and long-term outcomes in families with histories of child maltreatment.

Eligibility criteria: Inclusion Criteria:

* Families referred to service agency for child maltreatment prevention services
* Families with children between 2-1/2 and 12 years of age

Exclusion Criteria:

* Parents with cognitive, psychiatric, or social conditions that would limit their ability to provide voluntary consent or benefit from the intervention
* Parents who have sexually abused their children

Primary outcomes:
measure: Incidents of child maltreatment 1-3 years post-treatment
Secondary outcomes:
measure: Parenting behaviors, attitudes, and functioning assessed during and post-intervention
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Sciences Center
state: Oklahoma
Study officials:
affiliation: University of Oklahoma
name: Mark J Chaffin, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02910765: Methylene Blue and Ozone in Early Sepsis
Official title: Methylene Blue and Ozone in Early Sepsis , a Randomized Double Blind Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Sepsis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2016-09-22
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: effects of methylene blue and ozone O3 therapy effects in early sepsis management , and their implications upon outcome

Detailed description: effects of methylene blue on inducible nitric oxide messenger RNA transcription and protein expression are well evident in vasoplegia ,and septic shock . In the same time , ozone O3 therapy is also valuable in immune-modulation in multiple pathologies . our study collaborate both methylene blue and Ozone in early sepsis management , and we will evaluate the global medical progress , ICU stay , Morbidity and mortality

Eligibility criteria: Inclusion Criteria:

* early sepsis Adults patients

Exclusion Criteria:

* cardiac problems Glucose-6-Phosphate-Dehydrogenase Insufficiency Ozone Allergy Recent Myocardial Infarction Active Hyperthyroidism Thrombocytopenia Pregnancy Contraindications

Primary outcomes:
measure: APACHE score
timeFrame: 7 days
Secondary outcomes:
measure: ICU stay
timeFrame: 30 days
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Emad Zarief K Said, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01543165: Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic
Official title: A Single Center, Prospective Randomized Double-blind Trial: Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Renal Colic
Keywords: Renal colic
Analgesia
Nefopam
Ketorolac
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Pharmbio Korea
First posted: 2012-03-02
Enrollment: 111
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to see whether the combination regimen of ketorolac and nefopam is superior to that of ketorolac and morphine in controlling ureter stone-related acute flank pain.

Detailed description: The balanced analgesia regimen using both ketorolac and morphine is the most effective choice in controlling urolithiasis related acute pain. Previous animal and human studies reported that combination regimen of ketoprofen and nefopam showed synergistic effect in pain control. We hypothesized that using nefopam instead of morphine for ketorolac based combination analgesia will produce similar pain reduction without causing opioid-related side effect.

Eligibility criteria: Inclusion Criteria:

* Acute flank with visual analog pain scale score equal or more than 5
* and most possible diagnosis after initial clinical exam is acute renal colic

Exclusion Criteria:

* Pregnant or lactating women
* Patients whose use of any of the study drugs is contraindicated
* Patients with documented renal or hepatic failure or those with clinical findings suggesting the diagnoses
* Recent episode of acute myocardial infarction or patients with significant heart failure
* Patients with documented gastric/duodenal ulcer or those with clinical findings suggesting the diagnoses
* Patients with bleeding tendency
* Patients who have history of any seizure
* Patients with documented organic brain injury
* Patients taking warfarin
* Patients whose primary diagnosis is not renal colic

Primary outcomes:
measure: Amount of pain reduction by visual analog pain scale
timeFrame: At 30 and 60 minutes after primary study drug administration
Secondary outcomes:
measure: Additional analgesia requested by enrolled patients
timeFrame: At 30 and 60 minutes after primary study drug administration
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Kyeongi-do
Study officials:
References:
Clinical trial NCT00444665: Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
Official title: Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Glaucoma
Keywords: Glaucoma
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2007-03-08
Enrollment: 750
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.


Eligibility criteria: Inclusion Criteria:

* Adults with a clinical diagnosis of ocular hypertension, or primary open-angle, pigment dispersion or exfoliation glaucoma in at least one eye (study eye)

Exclusion Criteria:

* Age

Primary outcomes:
measure: Ocular Surface Disease Symptoms
Secondary outcomes:
measure: Intraocular pressure
Other outcomes:
Locations:
city: Fridley
country: United States
facility: Fridley
state: Minnesota
Study officials:
affiliation: Alcon Research
name: Mark Jasek, PhD
role: STUDY_DIRECTOR
References:
citation: Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008 Sep;2(3):613-21. doi: 10.2147/opth.s3881.